Disease · MONDO_0005419
Comparisons in its trials33
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 33
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Modafinil vs Placebo: Reduction of Craving | 32 of 142 | 10 of 68 | 210 | NCT00520286 | Trial comparisons |
| Modafinil vs Placebo: serious adverse events | 0 of 142 | 5 of 68 | 210 | NCT00520286 | Trial comparisons |
| Bupropion vs Placebo: Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use | 65 of 100 | 76 of 104 | 204 | NCT00687713 | Trial comparisons |
| Bupropion vs Placebo: Number of Subjects Showing Abstinence | 14 of 100 | 20 of 104 | 204 | NCT00687713 | Trial comparisons |
| Bupropion vs Placebo: serious adverse events | 1 of 100 | 3 of 104 | 204 | NCT00687713 | Trial comparisons |
| Topiramate vs Placebo Oral Tablet: serious adverse events | 3 of 69 | 8 of 71 | 140 | NCT00345371 | Trial comparisons |
| Ibudilast vs Placebo: Methamphetamine Use | 9 of 64 | 10 of 61 | 125 | NCT01860807 | Trial comparisons |
| Ibudilast vs Placebo: deaths from any cause | 0 of 64 | 0 of 61 | 125 | NCT01860807 | Trial comparisons |
| Ibudilast vs Placebo: serious adverse events | 2 of 64 | 1 of 61 | 125 | NCT01860807 | Trial comparisons |
| Citicoline vs Placebo: serious adverse events | 2 of 72 | 0 of 32 | 104 | NCT00950352 | Trial comparisons |
| Aripiprazole vs Placebo: serious adverse events | 3 of 45 | 4 of 45 | 90 | NCT00497055 | Trial comparisons |
| Modafinil vs Placebo: Retention | 14 of 34 | 13 of 37 | 71 | NCT00469508 | Trial comparisons |
| Modafinil vs Placebo: serious adverse events | 3 of 34 | 1 of 37 | 71 | NCT00469508 | Trial comparisons |
| Active Comparator: vs Placebo Comparator:: serious adverse events | 1 of 30 | 1 of 30 | 60 | NCT00497081 | Trial comparisons |
| Naltrexone With Ecological Momentary Intervention vs Placebo With Ecological Momentary Intervention: deaths from any cause | 0 of 40 | 0 of 20 | 60 | NCT04791969 | Trial comparisons |
| Naltrexone With Ecological Momentary Intervention vs Placebo With Ecological Momentary Intervention: serious adverse events | 2 of 40 | 0 of 20 | 60 | NCT04791969 | Trial comparisons |
| Vigabatrin vs Placebo: The Proportion of Subjects in Each Treatment Group Who Are Amphetamine Abstinent During the Last 2 Weeks of the Treatment Phase (Weeks 11 and 12). | 4 of 28 | 2 of 27 | 55 | NCT00730522 | Trial comparisons |
| Vigabatrin vs Placebo: deaths from any cause | 0 of 28 | 0 of 27 | 55 | NCT00730522 | Trial comparisons |
| Vigabatrin vs Placebo: serious adverse events | 2 of 28 | 0 of 27 | 55 | NCT00730522 | Trial comparisons |
| Sugar Pill vs Varenicline: End of Treatment Abstinence | 5 of 25 | 4 of 27 | 52 | NCT01365819 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005419/comparisons